Fred C Tenover1, L Clifford McDonald. 1. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. fnt1@cdc.gov
Abstract
PURPOSE OF REVIEW: This review updates information on the development and spread of vancomycin resistance in staphylococci and enterococci. RECENT FINDINGS: New information on the genetic characterization of vancomycin-resistant Staphylococcus aureus isolates from the US indicates that each of the four was the result of an independent genetic event. New data suggest that vancomycin-intermediate S. aureus isolates, particularly those showing heteroresistance, are clinically significant. Finally, vancomycin-resistant enterococci continue to be reported from around the world. Novel infection control measures, however, may aid in reducing the spread of these organisms in healthcare settings. SUMMARY: The exchange of genetic information, particularly the vanA gene, between and among staphylococci and enterococci will continue to challenge physicians, microbiologists, and infection control practitioners in efforts to identify, treat, and prevent infections with these pathogens.
PURPOSE OF REVIEW: This review updates information on the development and spread of vancomycin resistance in staphylococci and enterococci. RECENT FINDINGS: New information on the genetic characterization of vancomycin-resistant Staphylococcus aureus isolates from the US indicates that each of the four was the result of an independent genetic event. New data suggest that vancomycin-intermediate S. aureus isolates, particularly those showing heteroresistance, are clinically significant. Finally, vancomycin-resistant enterococci continue to be reported from around the world. Novel infection control measures, however, may aid in reducing the spread of these organisms in healthcare settings. SUMMARY: The exchange of genetic information, particularly the vanA gene, between and among staphylococci and enterococci will continue to challenge physicians, microbiologists, and infection control practitioners in efforts to identify, treat, and prevent infections with these pathogens.
Authors: Willem J B Van Wamel; Antoni P A Hendrickx; Marc J M Bonten; Janetta Top; George Posthuma; Rob J L Willems Journal: Infect Immun Date: 2006-11-21 Impact factor: 3.441
Authors: Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies Journal: Antimicrob Agents Chemother Date: 2006-09 Impact factor: 5.191
Authors: Karen C Carroll; Anita P Borek; Chad Burger; Brian Glanz; Hasan Bhally; Susan Henciak; Diane C Flayhart Journal: J Clin Microbiol Date: 2006-06 Impact factor: 5.948
Authors: Benjamin P Howden; Patrick G P Charles; Paul D R Johnson; Peter B Ward; M Lindsay Grayson Journal: Antimicrob Agents Chemother Date: 2005-11 Impact factor: 5.191
Authors: William L Galanter; Andrew Applebaum; Viveka Boddipalli; Abel Kho; Michael Lin; David Meltzer; Anna Roberts; Bill Trick; Surrey M Walton; Bruce L Lambert Journal: J Med Syst Date: 2013-02-05 Impact factor: 4.460
Authors: Katherine Reyes; Rushdah Malik; Carol Moore; Susan Donabedian; Mary Perri; Laura Johnson; Marcus Zervos Journal: J Clin Microbiol Date: 2009-12-09 Impact factor: 5.948